{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:02:00Z","timestamp":1790740920398,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.102963","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:32:59Z","timestamp":1785846779000},"page":"102963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adjuvant apatinib therapy following concurrent chemoradiotherapy in patients with high-risk nasopharyngeal carcinoma: A multicenter, prospective phase 2 study"],"prefix":"10.1016","volume":"72","author":[{"given":"Chen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkai","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102963_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102963_bib0002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0003","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet L. Eng."},{"key":"10.1016\/j.tranon.2026.102963_bib0004","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and Cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102963_bib0005","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102963_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2021.12.029","article-title":"Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial","volume":"167","author":"Tang","year":"2022","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2019.06.2549","article-title":"The Association Between the Development of Radiation Therapy, Image Technology, and Chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012","volume":"105","author":"Sun","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.tranon.2026.102963_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1331064","article-title":"Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies","volume":"14","author":"Xia","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102963_bib0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41419-021-03845-y","article-title":"Nuclear exosome HMGB3 secreted by nasopharyngeal carcinoma cells promotes tumour metastasis by inducing angiogenesis","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.102963_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16940-y","article-title":"The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells","volume":"7","author":"Akbarzadeh","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102963_bib0012","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1097\/00005537-200012000-00017","article-title":"The relationship between microvessel density, the expression of Vascular Endothelial Growth Factor (VEGF), and the extension of nasopharyngeal carcinoma","volume":"110","author":"Guang-Wu","year":"2000","journal-title":"Laryngoscope"},{"key":"10.1016\/j.tranon.2026.102963_bib0013","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2026.102963_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.422","article-title":"Apatinib promotes autophagy and apoptosis through VEGFR2\/STAT3\/BCL-2 signaling in osteosarcoma","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.102963_bib0015","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hed.27636","article-title":"An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent\/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375)","volume":"46","author":"Wei","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.tranon.2026.102963_bib0016","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2147\/DDDT.S244102","article-title":"Safety and feasibility of low-dose apatinib combined with S-1 as the second-line therapy or beyond in Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma","volume":"14","author":"Zhou","year":"2020","journal-title":"Drug. Devel. Ther."},{"key":"10.1016\/j.tranon.2026.102963_bib0017","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.22.01450","article-title":"Camrelizumab plus Apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study","volume":"41","author":"Ding","year":"2023","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0018","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-024-45126-0","article-title":"Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial","volume":"15","author":"Liang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102963_bib0019","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ijrobp.2022.04.049","article-title":"Adjuvant apatinib in nasopharyngeal carcinoma with residual Epstein-Barr Virus DNA after radiation therapy: a biomarker-driven, phase 2 trial","volume":"113","author":"Liu","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.tranon.2026.102963_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas. Dermosifiliogr."},{"key":"10.1016\/j.tranon.2026.102963_bib0021","article-title":"The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.tranon.2026.102963_bib0022","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis","volume":"24","author":"Petit","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0023","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.02764","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099","volume":"41","author":"Al-Sarraf","year":"2023","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0024","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/cncr.33626","article-title":"Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: a multicenter, single-arm, prospective phase 2 study","volume":"127","author":"Ruan","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102963_bib0025","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S1470-2045(23)00232-2","article-title":"Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"24","author":"Liu","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0026","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006502","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"2","author":"Koch","year":"2012","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"key":"10.1016\/j.tranon.2026.102963_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117106","article-title":"Therapeutic potentials of Apatinib in cancer treatment: possible mechanisms and clinical relevance","volume":"241","author":"Fathi Maroufi","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.tranon.2026.102963_bib0028","doi-asserted-by":"crossref","first-page":"5152072","DOI":"10.1155\/2019\/5152072","article-title":"Apatinib promotes apoptosis of pancreatic cancer cells through downregulation of hypoxia-inducible factor-1\u03b1 and increased levels of reactive oxygen species","volume":"2019","author":"He","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"10","key":"10.1016\/j.tranon.2026.102963_bib0029","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41419-018-1054-3","article-title":"Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer","volume":"9","author":"Feng","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tranon.2026.102963_bib0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primer."},{"key":"10.1016\/j.tranon.2026.102963_bib0031","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41417-022-00453-6","article-title":"Exosomal HMGA2 protein from EBV-positive NPC cells destroys vascular endothelial barriers and induces endothelial-to-mesenchymal transition to promote metastasis","volume":"29","author":"Li","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.tranon.2026.102963_bib0032","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdq629","article-title":"Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation","volume":"22","author":"Hui","year":"2011","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0033","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-10-3409","article-title":"A Phase II study of pazopanib in Asian patients with recurrent\/metastatic nasopharyngeal carcinoma","volume":"17","author":"Lim","year":"2011","journal-title":"Clin. Cancer. Res. J. Am. Assoc. Cancer. Res."},{"key":"10.1016\/j.tranon.2026.102963_bib0034","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/1078-0432.CCR-17-1667","article-title":"Efficacy, safety, and pharmacokinetics of Axitinib in nasopharyngeal carcinoma: a preclinical and phase II correlative study","volume":"24","author":"Hui","year":"2018","journal-title":"Clin. Cancer. Res. J. Am. Assoc. Cancer. Res."},{"key":"10.1016\/j.tranon.2026.102963_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41419-024-07327-9","article-title":"Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.102963_bib0036","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(11)70303-5","article-title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0037","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13014-022-02104-4","article-title":"Efficacy of concurrent chemoradiotherapy plus endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study","volume":"17","author":"Yin","year":"2022","journal-title":"Radiat. Oncol. L. Engl."},{"key":"10.1016\/j.tranon.2026.102963_bib0038","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2026.102963_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1101063","article-title":"Efficacy and safety of apatinib versus sorafenib\/placebo in first-line treatment for intermediate and advanced primary liver cancer: a systematic review and meta-analysis","volume":"14","author":"Peng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102963_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105222","article-title":"Efficacy and safety of apatinib in recurrent\/metastatic nasopharyngeal carcinoma: a pilot study","volume":"115","author":"Huang","year":"2021","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.tranon.2026.102963_bib0041","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10637-020-00925-2","article-title":"Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study","volume":"38","author":"Li","year":"2020","journal-title":"Invest. New Drugs"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:41:38Z","timestamp":1790739698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S1936523326002998"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102963","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant apatinib therapy following concurrent chemoradiotherapy in patients with high-risk nasopharyngeal carcinoma: A multicenter, prospective phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102963"}}